Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Drug allergy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    212 result(s) found for: Drug allergy. Displaying page 5 of 11.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-002689-19 Sponsor Protocol Number: Allo-Relapse-2011 Start Date*: 2011-11-22
    Sponsor Name: [...]
    1.
    2. Haukeland University Hospital
    Full Title: TREATMENT OF RELAPSED ACUTE LEUKEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: DISEASE STABILIZATION THROUGH CHEMOTHERAPY, IMMUNOMODULATORY TREATMENT AND IMMUNOTHERAPY
    Medical condition: Allotransplanted patients with early acute leukemia repse (within 1 year after transplant)
    Disease:
    Population Age: Adults Gender:
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-005125-20 Sponsor Protocol Number: M16-045 Start Date*: 2018-09-20
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis
    Medical condition: Moderate and Severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Trial now transitioned) FI (Trial now transitioned) DE (Ongoing) DK (Trial now transitioned) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) BG (Trial now transitioned) HR (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001142-10 Sponsor Protocol Number: MOR106-CL-201 Start Date*: 2018-04-26
    Sponsor Name:Galapagos N.V.
    Full Title: A Phase II, randomized, double-blind, placebo-controlled repeated-dose study to evaluate the efficacy, safety, tolerability, and PK/PD of intravenously administered MOR106 in adult subjects with mo...
    Medical condition: atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005212-22 Sponsor Protocol Number: CC-93538-AD-001 Start Date*: 2021-09-10
    Sponsor Name:Celgene International II Sàrl
    Full Title: A Phase 2, Multicenter, Global, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Cendakimab (CC-93538) in Adult Subjects with Moderate to Se...
    Medical condition: ATOPIC DERMATITIS
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2014-000097-19 Sponsor Protocol Number: TRANCHE Start Date*: 2016-06-10
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: Open, comparative, randomized study on the efficacy, safety and bioavailability of highly concentrated inhaled epinephrine (4 mg L-epinephrine / ml, Infectokrupp® Inhal) versus epinephrine autoinje...
    Medical condition: Food allergy
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-003403-13 Sponsor Protocol Number: CQAX576A2104 Start Date*: 2007-12-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A proof of concept study of the effects of QAX576 (an interleukin-13 monoclonal antibody) on allergic inflammation following out of allergy season repeated nasal allergen challenge in subjects with...
    Medical condition: Seasonal allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001723 Allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-000608-13 Sponsor Protocol Number: MK-4117-201 Start Date*: 2017-02-09
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A phase III multicentre, parallel-group, randomized, placebo-controlled, double-blind clinical trial to study the efficacy and safety of MK-4117 in Japanese subjects with chronic urticaria.
    Medical condition: Chronic urticaria (a skin condition caused by an allergy)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10052568 Urticaria chronic PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-021349-36 Sponsor Protocol Number: VRP100419 (CHDR1018) Start Date*: 2010-11-08
    Sponsor Name:Verona Pharma plc
    Full Title: Randomised, Double-Blind, Placebo-Controlled Evaluation of the Safety and Duration of Action of 2 Single Inhaled Doses, 0.036 mg/kg (12X) and 0.072 mg/kg (24X), of RPL554, a Dual PDE 3/4 Inhibitor,...
    Medical condition: Allergic Asthma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002166-40 Sponsor Protocol Number: RD.06.SPR.201591 Start Date*: 2021-11-18
    Sponsor Name:Galderma S.A.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis with Inadequate Response to or for Whom C...
    Medical condition: Moderate-to-Severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) LV (Completed) ES (Ongoing) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000333-31 Sponsor Protocol Number: PQGrass205 Start Date*: 2017-09-13
    Sponsor Name:Allergy Therapeutics (UK) Ltd.
    Full Title: A multi-centre, randomised, double blind, placebo controlled study to determine the optimal effective and safe dose of Pollinex Quattro Grass 1.0 mL (Allergy Therapeutics, (UK) Ltd.) for the treatm...
    Medical condition: Grass pollen-induced seasonal allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-004336-28 Sponsor Protocol Number: PQBirch203 Start Date*: 2013-08-19
    Sponsor Name:Allergy Therapeutics (UK) Ltd.
    Full Title: A multi-centre, double-blind dose-ranging study to evaluate the efficacy and safety/tolerability of Birch Modified Allergen Tyrosine-adsorbed + MPL (POLLINEX Quattro® Birch) in Subjects with season...
    Medical condition: seasonal allergic rhinoconjunctivitis due to birch pollen
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-002301-29 Sponsor Protocol Number: SL-51A Start Date*: Information not available in EudraCT
    Sponsor Name:ROXALL Medicina España S.A.
    Full Title: PHASE II STUDY TO ASSESS THE TOLERABILITY, SAFETY AND EFFICACY OF SUBLINGUAL IMMUNOTHERAPY IN PATIENTS SUFFERING FROM GRASS POLLEN ALLERGY
    Medical condition: Patients with grass pollen related allergic rhinitis/rhino-conjunctivitis (with or without well controlled asthma).
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002321-22 Sponsor Protocol Number: SL-71A Start Date*: 2020-08-06
    Sponsor Name:Roxall Medicina España S.A.
    Full Title: PHASE II STUDY TO ASSESS THE TOLERABILITY, SAFETY AND EFFICACY OF SUBLINGUAL IMMUNOTHERAPY IN PATIENTS SUFFERING FROM HOUSE DUST MITE ALLERGY
    Medical condition: Patients with house dust mites related allergic rhinitis/rhino-conjunctivitis (with or without well controlled asthma).
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000376-26 Sponsor Protocol Number: ZPL521/101 Start Date*: 2016-05-09
    Sponsor Name:Ziarco Pharma Ltd
    Full Title: A Randomised, Adaptive Design, Double-Blind (3rd Party Open), Placebo Controlled, Sequential Group Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Applica...
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002932-10 Sponsor Protocol Number: DRM06-AD04 Start Date*: 2020-03-06
    Sponsor Name:Dermira, a wholly owned subsidiary of Eli Lilly and Company
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) ES (Completed) PL (Completed) EE (Completed) FR (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2021-000448-23 Sponsor Protocol Number: RD.06.SPR.118126 Start Date*: 2022-04-05
    Sponsor Name:Galderma S.A.
    Full Title: A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Sever...
    Medical condition: Moderate-to-Severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) HU (Trial now transitioned) PL (Trial now transitioned) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003639-41 Sponsor Protocol Number: UP0089 Start Date*: 2020-11-06
    Sponsor Name:UCB Biopharma SRL
    Full Title: Phase 1/2A, randomized, placebo-controlled, single-ascending dose (Part A, participant- and investigator-blind) and repeated-dose (Part B, participant-, investigator-, and sponsor-blind) study to i...
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) BG (Completed) DE (Completed) ES (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000725-28 Sponsor Protocol Number: KY1005-CT05_(DRI17366) Start Date*: 2022-01-24
    Sponsor Name:Kymab Limited
    Full Title: A Phase IIb, Randomised, Double Blind, Placebo Controlled, Parallel Group, Multicentre Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate to Severe At...
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed) BG (Completed) HU (Completed) PL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2018-002225-26 Sponsor Protocol Number: 280789 Start Date*: 2019-10-22
    Sponsor Name:HOSPITAL UNIVERSITARIO FUNDACION ALCORCON
    Full Title: EVALUATION OF THE COFACTORS IN THE MAINTENANCE PHASE REACTIONS AFTER MILK AND EGG ORAL IMMUNOTHERAPY
    Medical condition: Investigate the role of the drug in the possible allergic reactions as a cofactor
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002401-56 Sponsor Protocol Number: I9N-MC-FCAB Start Date*: 2019-04-29
    Sponsor Name:Eli Lilly & Company
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3375880 in Adult Subjects with Moderate-to-Severe Atopic Dermatitis
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) AT (Prematurely Ended) FR (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 00:50:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA